As we observed a decreased cell growth and proliferation in all the BC cell lines after treatment with the combination therapy, we further wanted to evaluate the effect of this combination therapy on the PI3K/Akt/mTOR pathway, which is an important regulator of cell growth and proliferation. The gene discussed is MTOR; the disease is breast cancer.